Financial Data and Key Metrics Changes - Q3 revenue reached $27.4 million, representing an 18% increase compared to $23.3 million in Q3 2024 [6][11] - Adjusted EBITDA for Q3 was $1 million, a significant improvement from a negative $3.8 million in Q3 2024 [12] - Gross profit increased by 25% to $17.9 million, with gross margins improving to 65.2% from 61.2% in the prior year [12] - Net loss decreased by 28% to $8 million compared to $11.2 million in the previous year [12] Business Line Data and Key Metrics Changes - Total billable volume for Q3 was approximately 33,000 tests, with tissue-based tests increasing by 18% and liquid-based tests growing by 65% year-over-year [11][12] - Tissue-based tests accounted for 76% of revenues in Q3 [11] Market Data and Key Metrics Changes - The company reported a compound annual growth rate of 45% in its sales organization over the last four years, while reducing sales and marketing expenses as a percentage of revenue [4] - The integration of the Exosome Diagnostics business is expected to enhance the company's market position in precision diagnostics for urology [3][10] Company Strategy and Development Direction - The company is focused on integrating the ExoDx acquisition to optimize sales and operational efficiencies, with a strategic expansion of the sales organization from 50 to 60 direct sales representatives [7][10] - MDxHealth aims to maintain its revenue guidance of $108-$110 million for 2025, despite the decision to forgo the germline offering [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustained top-line growth and advancing operating profitability, following two consecutive quarters of positive adjusted EBITDA [5][14] - The company is committed to enhancing the customer experience and operational excellence, which are seen as critical to driving future growth [14][15] Other Important Information - Cash and cash equivalents as of September 30, 2025, were reported at $32 million [13] - The company is prioritizing the integration of ExoDx and expects to provide updates on progress in early 2026 [10][14] Q&A Session Summary Question: Contribution of ExoDx in the quarter - Management indicated that there was no material contribution from ExoDx in Q3 due to the timing of the acquisition, but they remain confident in meeting revenue guidance [18][19] Question: Performance of GPS - GPS and ConfirmMDx tests reported an 18% growth, with management confident in maintaining this performance despite a slight slowdown in patient flow [23][24] Question: Germline test strategy - The company decided to forgo the germline test for now, focusing resources on the ExoDx integration, but plans to reevaluate the opportunity in 2026 [10][56] Question: Gross margins and ExoDx impact - Management expects ExoDx to be neutral to accretive to gross margins, with a clearer view anticipated after a couple of quarters of integration [59][60] Question: Sales team expansion - The sales team was expanded by adding 10 reps from ExoDx, with territory adjustments made to optimize coverage [67][68]

Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 Q3 revenues increased by 18% to $27.4 millionAdjusted EBITDA profitability of $1.0 million for Q3Acquisition of ExoDx business from Bio-Techne CorporationConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA – November 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the three and ...

Core Insights - MDxHealth SA will release its financial results for the third quarter ended September 30, 2025, after market close on November 12, 2025 [1] - A conference call with live Q&A will be held on the same day at 4:30 PM ET / 22:30 CET [2] Company Overview - MDxHealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment [3] - The company's tests are based on proprietary genomic, epigenomic, exosomal, and other molecular signatures, assisting physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases [3] - The U.S. headquarters and laboratory operations are located in Irvine, California, with additional labs in Waltham, Massachusetts, and Plano, Texas; European headquarters are in Herstal, Belgium [3]

Core Viewpoint - The article emphasizes the importance of identifying and maintaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for sustaining momentum in stocks [1]. Group 1: Recent Price Strength Screen - The "Recent Price Strength" screen is a unique short-term trading strategy that helps identify stocks with strong fundamentals capable of maintaining an uptrend [2]. - Stocks that pass this screen are typically trading in the upper portion of their 52-week high-low range, indicating bullish sentiment [2]. Group 2: MDxHealth SA (MDXH) Analysis - MDxHealth SA (MDXH) has shown a significant price increase of 100.8% over the past 12 weeks, indicating strong investor interest [3]. - A recent price increase of 7.5% over the last four weeks suggests that the upward trend is still intact for MDXH [4]. - MDXH is currently trading at 91.7% of its 52-week high-low range, suggesting it may be on the verge of a breakout [4]. Group 3: Fundamental Strength - MDXH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5]. - The Zacks Rank system has a strong track record, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988 [6]. - The Average Broker Recommendation for MDXH is 1 (Strong Buy), indicating high optimism from the brokerage community regarding its near-term price performance [6]. Group 4: Additional Investment Opportunities - Besides MDXH, there are other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting further investment opportunities [7]. - The article encourages exploring over 45 Zacks Premium Screens tailored to different investing styles for potential stock picks [7].

MDxHealth SA (NASDAQ:MDXH) is among the best fundamentally strong penny stocks to buy right now. On September 15, 2025, MDxHealth SA (NASDAQ:MDXH) announced the completion of its acquisition of Bio-Techne Corporation’s ExoDx business, including the ExoDx Prostate test. This $15 million transaction is part of the company’s plan to strengthen its precision diagnostics portfolio. Earlier on August 5, 2025, MDxHealth SA (NASDAQ:MDXH) signed a definitive agreement for the takeover with payment structured over ...

Acquisition Announcement - MDxHealth has completed the acquisition of Exosome Diagnostics, including the ExoDx Prostate test, from Bio-Techne Corporation [1][2] - The total consideration for the acquisition is $15 million, with $5 million in stock paid at closing and $2.5 million to be paid annually over the next four years [2] Company Overview - MDxHealth is a leading precision diagnostics company that provides molecular information to personalize patient diagnosis and treatment [4] - The company's tests utilize proprietary genomic, epigenetic, exosomal, and other molecular technologies to assist in the diagnosis and prognosis of urologic cancers and diseases [4] - MDxHealth operates its U.S. headquarters and laboratory in Irvine, California, with additional facilities in Waltham, Massachusetts, and Plano, Texas, while its European headquarters is located in Herstal, Belgium [4]

Financial Performance - Revenue for the six months ended June 30, 2025, increased by 21% to $50.9 million compared to $42.0 million for the same period in 2024[2] - Gross profit rose by 30% to $33.1 million, with gross margins improving to 65% from 60.4% in the prior year[3] - Operating loss decreased by 54% to $6.5 million, down from $14.0 million in the previous year, driven by higher revenues and gross profit[4] - Net loss for the period was $16.6 million, a 17% reduction from $20.0 million in the prior year[4] - Basic and diluted loss per share improved by 55% to $(0.33) from $(0.73) year-over-year[2] - Tissue-based revenue increased to $43.2 million in the first half of 2025, up from $33.7 million in the same period of 2024, representing a growth of 28%[29] Cash and Liquidity - As of June 30, 2025, the company had cash and cash equivalents of $32.8 million, indicating sufficient liquidity for at least the next twelve months[7] - Cash and cash equivalents decreased to $32.8 million as of June 30, 2025, down from $46.8 million at the beginning of the period[17] - The company expects to continue incurring net losses and significant cash outflows for at least the next twelve months[5] - The company expects continued losses and negative operating cash flows in the coming twelve months, but believes it has sufficient cash to continue operations for at least the next twelve months[25] Debt and Liabilities - The company entered into a $100 million Credit Agreement, with $55 million already advanced and additional amounts contingent on revenue requirements[9] - Total liabilities as of June 30, 2025, were $141.5 million, slightly down from $142.5 million at the end of 2024[15] - The company incurred a net cash outflow from operating activities of $4.2 million for the first half of 2025, compared to $9.8 million in the same period of 2024[17] - The company has an accumulated deficit of $386.1 million as of June 30, 2025[5] - The company’s accumulated deficit increased to $386.1 million as of June 30, 2025, from $369.5 million at the end of 2024[16] Expenses - The cost of sales for the first half of 2025 was $17.8 million, compared to $16.6 million in the same period of 2024[32] - For the six months ended June 30, 2025, research and development expenses decreased by $0.5 million, or 10%, primarily due to lower consulting, labor, and reagent costs[34] - Selling and marketing expenses decreased by $0.9 million, or 4%, primarily due to lower commission expenses for the same period[35] - General and administrative expenses increased by $0.9 million, or 8%, primarily due to stock-based compensation and overall business growth[36] Financial Adjustments and Acquisitions - Financial income for the period ended June 30, 2025, decreased by $0.5 million, or 32%, primarily due to the absence of a $1.0 million gain from fair value adjustments related to Exact Sciences warrants[39] - Total financial expenses increased by $3.8 million, or 50%, primarily from increases in loan and lease interest expense of $2.1 million and a $4.4 million increase in the fair value of GPS contingent consideration[40] - As of June 30, 2025, the contingent consideration related to the acquisition of GPS was assessed at $44.8 million, down from $67.3 million as of December 31, 2024[48] - The Company made its first earnout payment to Exact Sciences of $28.0 million on April 30, 2025, reducing the aggregate undiscounted amount due from $82.5 million to $54.5 million[47] - The Company signed an agreement to acquire Exosome Diagnostics, Inc. for a total consideration of $15 million, including $5 million in stock at closing and $2.5 million annually over the next four years[65] Contingent Consideration and Fair Value - The ending balance of contingent consideration liabilities as of June 30, 2025, was $45.5 million, down from $67.9 million at the end of 2024[56] - The fair value of the Company's option to prepay the OrbiMed Loan Facility was valued at $0.6 million as of June 30, 2025[55] - As of June 30, 2025, the fair value of the contingent consideration payable to Exact Sciences was adjusted to $54.5 million, down from $82.5 million after a $28.0 million earn-out payment[55] - The Company recorded a financial charge of $5.4 million and an additional charge of $0.1 million to other operating expenses as of June 30, 2025, due to fair-value adjustments[55] - The total fair value of granted warrants is estimated at $3.4 million, with an expense of $1.1 million recorded for the six months ended June 30, 2025[64] Warrants and Options - As of June 30, 2025, there are 6,210,976 warrants outstanding, with 1,699,431 vested warrants[60] - The Company used a discount rate of 20.69% for variable earnouts as of June 30, 2025[55] - The beginning balance of the OrbiMed prepayment option was $434,000 as of June 30, 2025, increasing to $625,000 by the end of the period[54] - The Company recorded a fair value change through profit and loss of $191,000 for the OrbiMed prepayment option during the first half of 2025[54]

分组1 - MDxHealth SA reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, but an improvement from a loss of $0.31 per share a year ago, indicating a surprise of -15.38% [1] - The company posted revenues of $26.61 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.02% and showing an increase from $22.16 million in the same quarter last year [2] - MDxHealth SA shares have increased by approximately 4.2% since the beginning of the year, while the S&P 500 has gained 7.6%, indicating underperformance relative to the broader market [3] 分组2 - The earnings outlook for MDxHealth SA is uncertain, with current consensus EPS estimates of -$0.11 for the coming quarter and -$0.52 for the current fiscal year, alongside expected revenues of $27.8 million and $108.5 million respectively [7] - The Zacks Industry Rank places the Medical Info Systems sector in the top 29% of over 250 Zacks industries, suggesting that companies in the top half of the rankings tend to outperform those in the bottom half by more than 2 to 1 [8] - The estimate revisions trend for MDxHealth SA was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating that the stock is expected to perform in line with the market in the near future [6]

Core Insights - MDxHealth reported a 20% year-over-year increase in Q2 revenues, reaching $26.6 million, marking the 17th consecutive quarter of 20% or greater revenue growth [1][3][8] - The company achieved positive adjusted EBITDA of $1.4 million for Q2, a significant improvement of $6.2 million compared to the same period last year [1][12] - MDxHealth announced the acquisition of Exosome Diagnostics from Bio-Techne for $15 million, which is expected to enhance revenue growth and be accretive to adjusted EBITDA [1][4][6] Financial Performance - Q2 revenue of $26.6 million represents a 20% increase from $22.2 million in the prior year [9][10] - Gross profit increased by 32% to $17.6 million, with gross margins improving to 66% from 60% [10][12] - Operating loss decreased by 74% to $1.9 million, while net loss improved by 36% to $7.4 million compared to the prior year [8][11][12] Acquisition Details - The acquisition of Exosome Diagnostics includes the ExoDx Prostate test and is structured as $15 million total consideration, with $5 million in stock at closing and $2.5 million annually over the next four years [6][4] - The ExoDx business is anticipated to contribute over $20 million in revenue in 2026 and accelerate MDxHealth's revenue growth rate to approximately 30% [6][4] - The transaction is expected to close in September 2025, subject to customary closing conditions [6] Market Position and Strategy - MDxHealth's growth is driven by strong demand for its tissue-based tests, including GPS and Confirm mdx [3][4] - The acquisition is seen as a strategic move to expand MDxHealth's capabilities in liquid-based diagnostics for prostate cancer, enhancing its leadership in this high-growth market [4][6] - The company reaffirmed its 2025 revenue guidance of $108-110 million following the acquisition announcement [4]

Core Viewpoint - MDxHealth SA has appointed Michael Holder as the Chair of the Audit Committee, succeeding Regine Slagmulder, and announced the resignation of CFO Ron Kalfus, with Scott McMahan taking over interim CFO responsibilities [1][3][4] Group 1: Leadership Changes - Michael Holder brings over 30 years of experience in biotech, medtech, and pharma, having held multiple executive roles including CEO and CFO [2] - Ron Kalfus will continue as CFO until July 30, 2025, after which Scott McMahan will assume the role on an interim basis [3][4] Group 2: Company Background - MDxHealth is a precision diagnostics company focused on providing molecular information for personalized patient diagnosis and treatment, particularly in urologic cancers [5] - The company operates its U.S. headquarters in Irvine, California, and has additional laboratory operations in Plano, Texas, with European headquarters in Herstal, Belgium [5]